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Abstract
Background: Atypical Beijing genotype Mycobacterium tuberculosis strains are widespread in South Africa and have
acquired resistance to up to 13 drugs on multiple occasions. It is puzzling that these strains have retained fitness
and transmissibility despite the potential fitness cost associated with drug resistance mutations.
Methods: We conducted Illumina sequencing of 211 Beijing genotype M. tuberculosis isolates to facilitate the
detection of genomic features that may promote acquisition of drug resistance and restore fitness in highly
resistant atypical Beijing forms. Phylogenetic and comparative genomic analysis was done to determine changes
that are unique to the resistant strains that also transmit well. Minimum inhibitory concentration (MIC)
determination for streptomycin and bedaquiline was done for a limited number of isolates to demonstrate a
difference in MIC between isolates with and without certain variants.
Results: Phylogenetic analysis confirmed that two clades of atypical Beijing strains have independently developed
resistance to virtually all the potent drugs included in standard (pre-bedaquiline) drug-resistant TB treatment
regimens. We show that undetected drug resistance in a progenitor strain was likely instrumental in this resistance
acquisition. In this cohort, ethionamide (ethA A381P) resistance would be missed in first-line drug-susceptible
isolates, and streptomycin (gidB L79S) resistance may be missed due to an MIC close to the critical concentration.
Subsequent inadequate treatment historically led to amplification of resistance and facilitated spread of the strains.
Bedaquiline resistance was found in a small number of isolates, despite lack of exposure to the drug. The highly
resistant clades also carry inhA promoter mutations, which arose after ethA and katG mutations. In these isolates,
inhA promoter mutations do not alter drug resistance, suggesting a possible alternative role.
Conclusion: The presence of the ethA mutation in otherwise susceptible isolates from ethionamide-naïve patients
demonstrates that known exposure is not an adequate indicator of drug susceptibility. Similarly, it is demonstrated
that bedaquiline resistance can occur without exposure to the drug. Inappropriate treatment regimens, due to
missed resistance, leads to amplification of resistance, and transmission. We put these results into the context of
current WHO treatment regimens, underscoring the risks of treatment without knowledge of the full drug
resistance profile.
Keywords: Tuberculosis, Drug-resistant, Beyond-XDR-TB, Missed resistance, Weakened regimen, Whole genome
sequencing, Atypical Beijing, Bedaquiline
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Background
Drug-resistant tuberculosis (DR-TB) represents a glo-
bal health crisis, exacerbated by TB that is resistant
to most of the routinely used drugs [1–4]. Cases with
resistance beyond the four drugs/drug classes defining
extensively drug-resistant TB (XDR-TB, resistance to
isoniazid, rifampicin, at least one second-line inject-
able and a fluoroquinolone) are the result of further
acquisition of resistance [1–3], primary (transmitted)
resistance [4] or a combination thereof [5]. Strains of
the Beijing lineage of the Mycobacterium tuberculosis
complex have previously been associated with an in-
creased ability to develop multidrug resistance (MDR,
resistance to at least isoniazid and rifampicin) and
spread [6–8]. Examples are the documented outbreaks
in Russia [9] and South Africa (Gauteng Province)
[10], as well as the widespread transmission of a
highly resistant strain in the Eastern Cape (EC) Prov-
ince of South Africa [4]. The latter strains belong to
the atypical (ancient) subgroup of Beijing strains, also
termed Asia Ancestral 1 [11], ST11 [12], Lineage
2.2.2 [13], etc. [14], and are distinguished from typical
(modern) Beijing strains primarily through the ab-
sence of an IS6110 in the NTF-1 region (so desig-
nated by Plikaytis et al. [15]). This genotype is usually
seen at low frequency worldwide, with the notable
exception of Japan, Vietnam and Taiwan [16–20].
Similarly, drug-susceptible atypical Beijing strains are
generally present at low frequency in South African
settings [21]. However, in the EC, the atypical Beijing
strains are over-represented among drug-resistant TB
strains [4]. Furthermore, an increasing incidence of
atypical Beijing strains observed in the Western Cape
(WC) Province, in particular among XDR-TB patients
[21], suggests an influx through migration from the
EC. However, detailed studies have not yet been per-
formed. These data suggest a potential survival advan-
tage in drug-resistant atypical Beijing isolates from
the region, which enhances their ability to transmit
and cause disease, as well as overcome the potential
fitness cost associated with drug resistance [22, 23].
We aimed to interrogate the genomes of highly
resistant atypical Beijing strains (resistant to up to 13
drugs, Additional file 1) from the EC and WC
through whole genome sequencing (WGS), which
provides a thorough and unbiased understanding of
genome features pertaining to the evolution of myco-
bacterial strains. Our analysis included a small num-
ber of presumed drug-susceptible isolates of the same
genotype, as well as published [11, 24, 25] and un-
published genome sequences from typical and atypical
Beijing strains isolated from other South African re-
gions and from different settings across the globe to
describe evolutionary relationships.
Methods
Strain selection
In order to determine whether genomic changes account
for the apparent increased ability to acquire resistance
and spread, clinical isolates of the atypical Beijing geno-
type isolated from patients residing in the EC (n = 60)
and WC (n = 92), sampled between 1994 and 2016
(Additional file 2), were included in the study. Isolates
originating from the EC were selected for WGS based
on their genotypic (Sanger sequencing) drug resistance
profiles [4], reflecting the available diversity in terms of
number and type of mutations detected. Subsequently,
our sequence database, containing sequences of many
different studies and originating mostly from the WC,
was queried for sequences of the Beijing genotype, based
on Spolpred [26] results. The selection was a conveni-
ence sample, making use of available strains collected
for various studies, reflecting both an approximation of
the true population structure, and genomic variety. Only
a small number (n = 7) of presumed drug-susceptible
(based on routine phenotypic drug susceptibility testing
(DST) and limited Sanger sequencing) atypical Beijing
isolates with high-quality sequences were available, due
to its low prevalence in the population. Treatment
history and outcomes are unknown for all patients sam-
pled. Additional genome sequences analysed in this
study comprised of a selected variety of published
Beijing strains originating from South Africa and other
global settings [11, 24, 25]. The final selection (n = 59)
was made to represent only a small number of each
available typical Beijing subclade. These strains were in-
cluded to determine the phylogenetic relationship of
South African Beijing strains compared to global repre-
sentatives of Beijing genotype strains and to determine
changes that are unique to the atypical Beijing clade
(Additional file 2).
DNA sequencing
Clinical isolates were cultured under biosafety level 3
conditions on 7H10 media. The bacteria were heat-killed
prior to standard phenol/chloroform DNA extraction
[27]. Paired-end genomic libraries were prepared using
either TruSeq DNA Sample Preparation Kits V2
(Illumina Inc., San Diego, CA, USA) or NEBNext Ultra
DNA library prep kit for Illumina (New England
BioLabs) per manufacturers’ recommendations. Pooled
samples were sequenced on an Illumina HiSeq 2000 or
NextSeq 550, respectively.
DNA sequence analysis
The resultant paired-end sequencing data, as well as
published raw reads, were analysed using an in-house se-
quence analysis pipeline, as described by Black et al.
[28]. Briefly, Trimmomatic [29] was used to trim reads
Klopper et al. BMC Medicine           (2020) 18:24 Page 2 of 14
with a sliding window approach and an average phred
score of 20, prior to alignment to M. tuberculosis H37Rv
(GenBank NC000962.2) with three different algorithms,
namely Burrows-Wheeler aligner, NovoAlign and
SMALT [30–32]. The Genome Analysis Tool Kit
(GATK) [33] and Samtools [30] were used for variant
calling, while GATK was also used to identify areas of
zero coverage (areas deleted from the genome). Drug
resistance conferring mutations were identified using a
reference library [34]. Only high-quality sequences,
based on average read depth and percentage mapped
reads, and variants called by all combinations of align-
ment software and variant callers were used in further
analyses (Additional file 2). Alignments of the different
strains were inspected visually with Artemis (Sanger
Institute) [35] and Genomeview [36] to inspect boundar-
ies of large deletions. Large deletions were considered to
be true when there was a clear cut in stacked reads with
no reads covering the deleted region in Bamview in
Artemis. Apparent deletions, where some low-depth
reads were present, were judged individually by compar-
ing the region to that of other strains to gauge the
reliability of sequencing of the region. Where coverage
of a region seemed haphazard (e.g. in repetitive regions),
they were considered to have a wild-type genotype, as
were apparent deletion of genes that are noted to have
high sequence similarity to other genes in the M. tuber-
culosis genome.
Phylogeny
A sequence consisting of concatenated high-confidence
sequence variants (from coding and non-coding se-
quence) was prepared from each isolate. Known drug re-
sistance conferring variants as described by Coll et al.
[37], variants located in repeat regions, with quality
scores generated by Samtools below 200, per-base
coverage of less than 10 reads or heterogeneity fre-
quency below 0.8 were removed prior to compiling the
concatenated sequence. Cutoff values were chosen to re-
sult in high-confidence variant sites, which were subse-
quently written to a multi-FASTA alignment, which in
turn was used for phylogenetic inference in IQ-TREE
v1.5 [38]; gaps were excluded. ModelFinder [39] identi-
fied K3Pu+ASC+R4 as the most likely substitution
model, and the Maximum Likelihood tree was recon-
structed accordingly with 1000 standard nonparametric
bootstrap replicates. M. tuberculosis H37Rv, accession
NC000962.2, was used as an outgroup [40], but is not
shown on the figure. The subsequent tree was annotated
with drug resistance mutations, using the ggtree package
in R [41]. Clades were assigned based on the topology of
the tree, but also taking drug resistance markers into
account.
We performed linear regression analysis on the whole
tree, as well as on the AA1SA clade only, to determine if
a correlation exists between branch length and average
coverage. Additionally, we did a Student’s t test to deter-
mine whether read length (100 bp on Illumina HiSeq
2000 or 150 bp on Illumina NextSeq 550) influenced
average branch length.
It should be noted that within the context of this
study, we use the term “transmission” not in the sense of
direct person-to-person transmission, but rather reflect-
ing past and more recent events within an endemic
setting.
Comparative genomics
A SNP distance matrix was produced by comparing the
variants found between strains. This included variants
used in the phylogenetic analysis as well as drug resist-
ance causing mutations. A similar approach was used to
identify variants that occurred uniquely in different
phylogenetically assigned groups, but this analysis in-
cluded small insertions and deletions. Thus, the phyl-
ogeny, which did not include drug resistance causing
mutations or insertions and deletions, was used to in-
form grouping for further analysis which did include
these variants. Briefly, an in-house Python script was
used to calculate the number of variants unique to a se-
lected group of isolates (e.g. Clade A in Fig. 1), com-
pared to another group of isolates (e.g. Clade B in
Fig. 1). The output consists of three lists: (a) variants
unique to the group of interest, (b) variants unique to
the comparator group and (c) variants present in both
groups. The first and second lists (variants unique to
each group) were inspected for variants that are present
in all members of a given group, and the sum of these
was taken to be the minimum inter-clade distance.
Additionally, in the above example, variants that oc-
curred in all clade A and B isolates represent ancestral
variants, while variants that occurred in both groups, but
not in all members of either group, were considered
homoplastic. Variants occurring in all isolates from a
specific group, and not in other investigated isolates,
were considered defining of the group in question.
In a separate analysis, we inspected sequences for
known resistance-causing mutations that occurred at
frequencies lower than our 0.8 cutoff for the phylogeny
and comparative genomics, to detect emerging
resistance.
Variant analysis
Protein Variation Effect Analyzer (PROVEAN) v1.1 [42]
was used to predict whether individual variants that
were defining of a specific phylogenetic group would
disrupt protein function.
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Minimum inhibitory concentration determination for
ethionamide, streptomycin and bedaquiline
A selection of isolates with an ethA A381P mutation was
used to determine the minimum inhibitory concentra-
tion (MIC) of ethionamide (ETH) in the presence or
absence of inhA promoter mutations. MIC testing was
done at 5, 20 and 40 μg/ml ETH in a MGIT 960 BAC-
TEC™ (BD Diagnostic Systems, NJ, USA) instrument and
results analysed with Epicentre™ software. M. tubercu-
losis H37Rv (ATCC 27294) was used as a fully suscep-
tible control.
Similarly, additional isolates were selected based on
the presence of mutations associated with streptomycin
(SM) resistance, to determine the effect of gidB L79S
mutations at 0.5, 1 and 2 μg/ml SM on MIC.
Lastly, one isolate with a mutation in mmpL5 was
available for bedaquiline (BDQ) resistance testing at the
following concentrations: 0.125, 0.25, 0.5, 0.75 and 1 μg/
ml. Drug dilutions were prepared in polystyrene tubes.
Results
Phylogeny
A maximum likelihood (ML) phylogeny was generated
to contextualise South African Beijing strains in the glo-
bal perspective, focusing on the atypical Beijing group
called Asia Ancestral 1 (AA1), by Merker et al. [11]
(Fig. 1). The phylogenetic tree generated was based on
4627 variable sites (selection described in methods) in
211 isolates and was considered robust, with bootstrap
values well above 70 at all major branches, and in broad
Fig. 1 The annotated Maximum Likelihood phylogeny of various Beijing-family M. tuberculosis strains to demonstrate the relative position and
drug resistance mutation profiles of South African isolates (AA1SA) belonging to the Asian Ancestral 1 clade. The phylogeny indicates that the
branching of AA1 is the most ancient in the Beijing lineage, and suggests that various forms of Beijing was introduced into South Africa
independently. It appears that only one introduction of AA1 occurred, which subsequently evolved into different subclades. Clades: AA1SA, Asian
Ancestral 1 South Africa; AA1, Asian Ancestral 1; AA2, Asian Ancestral 2; AA3, Asian Ancestral 3. Asian Ancestral clades collectively comprise
atypical Beijing, while the remainder of the clades represent various forms of typical Beijing. Geographic origins: EC, Eastern Cape; WC, Western
Cape; KZN, KwaZulu-Natal; CA, Central Asia; EA, Eastern Asia; SAs, Southern Asia; EU, Europe; PA, Pacific; AF, Africa. Drug resistance mutations are
organised according to gene and type of resistance caused: ethA, ethionamide; katG and inhA, isoniazid; gidB, rpsL and rrs 514-region,
streptomycin; inhA prom(oter), isoniazid and ethionamide; embB, ethambutol; pncA, pyrazinamide; rpoB, rifampicin; rrs 1401-region, amikacin,
kanamycin, capreomycin; alr, terizidone/cycloserine; gyrA and gyrB, fluoroquinolones; mmpR, bedaquiline and clofazimine. We show all observed
mmpR mutations, as the role of these in conferring resistance is not well documented, although several different mutations in mmpR has been
implicated in resistance. Nodes with a bootstrap support of 70 or more are indicated by black circles. The phylogeny is rooted to H37Rv
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agreement with published phylogenies [11]. The
phylogeny showed that South African Beijing strains
(including typical and atypical) are interspersed with
strains from other global settings. Furthermore, some in-
dividual branches contain strains from different global
locations. These results suggest multiple introduction
events of Beijing strains into South Africa.
The South African strains of the AA1 genotype (Fig. 1)
have distinct features (described below) compared to
those identified elsewhere and broadly correspond to
Beijing sublineage 1 as described by Hanekom et al. [7].
For the purpose of this study, we propose to call this
clade AA1SA. Our phylogenetic analysis indicates that
this monophyletic Beijing clade consists of (sub)clades A
through D collectively (Fig. 1) and its close relation to
the AA1 strains was confirmed by the presence of all of
AA1-definitive SNPs reported by Merker et al. [11]. Our
phylogeny further affirms that the branching point basal
to Asian Ancestral 1 (AA1) is the most ancient within
the Beijing strain family (Fig. 1). While AA1SA are
abundant in the EC and WC, a limited number was
recorded by Cohen et al. [25] in KZN, as expected based
on the strain type distribution of the respective prov-
inces [21, 25]. Our analysis also revealed that within sub-
clades of AA1SA, pairwise SNP distance is variable. In
some instances, it is relatively low, considering the wide
temporal and geographical space of sampling: 88 isolate
pairs had a SNP distance of < 30. In the remaining iso-
lates, the SNP distance ranged from 31 to 286. A SNP
distance matrix is presented in Additional file 3. This
variability is also evident in the terminal branch lengths
of the phylogeny. We performed statistical analyses to
determine whether the variability in branch length may
be an artefact related to the average coverage or read
length. Linear regression analysis for average coverage
and terminal branch length indicates an R2 of 0.016
when considering the entire tree and 0.188 when only
the AA1SA genomes were included, suggesting no cor-
relation. Similarly, there was no difference in average
branch length comparing read lengths of 100 bp vs 150
bp (P > 0.05). Accordingly, we conclude that neither
average coverage nor read length is responsible for the
observed variable branch lengths.
Variants defining the AA1SA genotype
The AA1SA sublineage described here is defined by 86
AA1SA-specific variants, which distinguish it from all
other Beijing isolates investigated. This includes SNPs
and small insertions or deletions (Additional file 4) as
well as three large deletions (Table 1). Of the 86 SNPs,
45 (52.3%) were non-synonymous mutations (including
3 frameshift mutations) in coding regions, 26 (30.2%)
were synonymous and 14 (16.2%) were intergenic.
Twelve SNPs were found to be likely deleterious by
PROVEAN [42] analysis. Of these, 9 were in non-
essential genes with known or unknown function
(Table 2), namely Rv1877, ethA, desA3, cut5B and
Rv2303c (known function), and Rv0421c, Rv1053c,
Rv1907c, and Rv2923c (unknown function). Essential
genes harbouring predicted deleterious SNPs were mprB
(a two-component sensor kinase), ompA (an outer mem-
brane protein) and ruvA (a Holliday junction DNA
helicase).
The large deletions observed in all AA1SA isolates
(Table 1) include an 81-bp deletion in Rv1841c, a
1202-bp deletion from the region glnA3-Rv1879 and a
2385-bp deletion from Rv2016-Rv2019. The latter two
deletions encompass Region of Difference (RD) 163
and RD175a [45], respectively. However, the boundar-
ies of the deletions observed here and the previously
described RDs are very different, suggesting that these
were separate events. None of these deletions was
found in any investigated Beijing strains outside of
the AA1 genotype.
AA1SA subclades
It appears that a single AA1SA progenitor was intro-
duced into South Africa. After introduction into South
Africa, the AA1SA genotype diversified into four
subclades (clades A, B, C and D, with clade A further
Table 1 Genomic locations of observed large deletions in AA1SA isolates
Coordinates Size
(BP)
Genes affected Corresponding
RD
RD coordinates Presence Notes
2128380–2129581 1202 glnA3, Rv1879
(glutamine synthesis)
163 2127981–2128972 AA1SA, AA1 Additional mutations were found
in other genes involved in glutamine
synthesis (glnE ACG278ACA and
glnA2 CTG117TTG) in all AA1SA strains
2090364–2090443 81 Rv1841c – – AA1SA Non-essential conserved hypothetical
membrane protein
2263779–2266164 2385 Rv2016–Rv2019 175a 2263448–2263637 AA1SA, some AA1 Rv2016, Rv2018 and Rv2019 are
non-essential, conserved hypothetical
proteins. Rv2017 is a transcriptional
regulator, and essential for in vitro
growth [43].
BP base pairs, RD Region of Difference; from Tsolaki et al. [44]
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subdivided into A1 and A2 (Fig. 1)). While clade D is
not monophyletic within AA1SA, we treat it as such for
the purpose of comparison, as its members have at least
two things in common, which is not shared by clades A
to C, namely the apparent lack of transmissibility and
the limited number of drug resistance mutations ac-
quired. Clades A, B and C appear to have simultaneously
diverged from the same common progenitor, as sup-
ported by SNP data. However, the near-zero internal
branch lengths at the base of these clades should be
interpreted with caution; ML could not resolve this ap-
parent polytomy. While the three clades display se-
quence commonality, each clade has distinct defining
variants (Fig. 2, Additional file 5). Subclades A2 and A1
are sister taxa, as indicated by the phylogeny (Fig. 1),
and supported by the defining variants of each subclade
(Fig. 2, Additional file 5). While clades A1 and A2 have
seven variants in common that differentiate them from
clades B and C, clade A1 has four additional variants
that in turn differentiate it from clade A2. Although
Clade D is in fact polyphyletic, for the purposes of dis-
cussion, it is regarded as a single sister taxon to clades
A, B and C collectively.
Each of the AA1SA subclades evolved a unique drug
resistance mutation profile, including two major sub-
clades (clades A and B, Fig. 1) of highly drug-resistant
strains exhibiting strong clonal characteristics. These
clades have evolved from a common progenitor with a
minimum inter-clade distance of 17 SNPs. Clades A and
B each has a unique subset of known drug resistance
(DR) mutations (Fig. 1), and although these DR muta-
tions were excluded from the phylogenetic analysis, clus-
tering of strains into subclades was concordant with DR
mutation profile. Clade A2 is a sister taxon of A1 and
accordingly shows a subset of A1’s drug resistance
markers (Fig. 1), lacking the inhA promoter -15 muta-
tion in all cases, as well as the rrs 1401 mutation in the
majority.
All clade C and D isolates had a number of drug re-
sistance mutations, in addition to the AA1SA-defining
ethA A381P mutation (Fig. 1). The katG S315 T muta-
tion occurred in all clade C, but not clade D isolates, al-
though this mutation is known to be highly homoplastic
and is frequently observed in various strain types. Fur-
ther resistance mutations do not appear to conform to a
clear pattern within the phylogeny, suggestive of limited
transmission.
Special attention was drawn to the sequence of emer-
gence of further drug resistance mutations leading to
beyond-XDR phenotypes. Although “beyond-XDR” is
not an officially recognised term, we use it to broadly
describe strains that are resistant to additional first-, sec-
ond- and third-line drugs not included in the simplest
definition of XDR, emphasising the compounded nature
of resistance present. The phylogenomic inference
(Fig. 1) suggests that the most deeply rooted drug resist-
ance mutation within AA1SA was ethA A381P, followed
by katG S315T and rrs 514 a>c mutations causing ETH,
isoniazid (INH) and SM resistance, respectively. Interest-
ingly, a previously undescribed non-synonymous gidB
L79S mutation likely emerged in the progenitor of clades
A, B and C, around the same time of the first occurrence
of the katG mutation and before the rrs 514 mutation.
Subsequently, different clade-specific mutations in rpoB,
embB, pncA and inhA promoter were acquired, confer-
ring resistance to rifampicin (RIF), ethambutol, pyrazina-
mide and INH and ETH, respectively. Within clade B,
the chronology of acquisition of these four mutations is
Table 2 Deleterious mutations found in all AA1SA isolates
Amino
acid change
Gene Product Function PROVEAN score* Essentiality
P251L ompA (Rv0899) Outer membrane protein A Porin of low specific activity − 7.220 Essential
G59D Rv1877 Conserved integral
membrane protein
Involved in transport of drug
across the membrane
− 6.971 Non-essential
D53G cut5b (Rv3724B) Probable cutinase Cut5b Hydrolysis of cutin (a polyester
that forms the structure of
plant cuticle)
− 5.649 No info
Q103R Rv0421c Conserved hypothetical protein Unknown − 2.857 Non-essential
R27H Rv1053c Hypothetical protein Unknown − 5.000 Non-essential
P141S Rv1907c Hypothetical protein Unknown − 3.922 Non-essential
A46V Rv2923c Conserved protein Unknown − 3.437 Non-essential
R39W ruvA (Rv2593c) Probable Holliday junction
DNA helicase
Mediates Holliday junction migration
by localised denaturation/reannealing
− 6.219 Essential
A381P ethA (Rv3854c) Monooxygenase Activates the pro-drug ethionamide − 4.576 Non-essential
D304N mprB (Rv0982) Two-component sensor kinase Sensor part of a two component
regulatory system (MPRAB system)
− 4.284 Essential
*Mutations with scores below − 2.5 were considered deleterious
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indiscernible. However, in clade A1, the inhA promoter
mutation appears to have occurred last of these four
mutations, based on the absence of the inhA promoter
mutation in clade A2 strains. In a subset of clade B iso-
lates, an alr L113R mutation, conferring D-cycloserine
(CYC) and terizidone (TZD) resistance [46], occurred
after the afore-mentioned mutations (Fig. 1). rrs 1401
a>g mutations seen in clades A, B and C likely occurred
before the observed variety of gyrA mutations, suggest-
ing clonal expansion at pre-XDR level.
Our stringent filtering settings excluded any variant
occurring at a read frequency less than 0.8 at the given
genomic position for each isolate. Analysis of variants
occurring at lower frequency (< 0.8) revealed that this
method misses approximately 5% of fluoroquinolone re-
sistance within the sample set, as well as a small number
of other resistances (Additional file 6).
Minimum inhibitory concentration (MIC) determination
for ethionamide, streptomycin and bedaquiline
ETH MIC testing in BACTEC MGIT 960 confirmed that
all (n = 15) tested isolates carrying the AA1SA-specific
ethA A381P mutation have ETH MICs above the critical
concentration (5 μg/ml) [47] despite the lack of inhA
promoter mutations in several (12/15) of these isolates
(Table 3). The presence of an inhA promoter mutation
in addition to an ethA mutation did not appear to in-
crease the MIC at the concentrations tested.
MIC testing for SM resistance demonstrated MICs of
< 1 μg/ml for isolates with wild-type gidB and no other
SM resistance associated mutations (n = 6); 1 μg/ml for
isolates with the gidB L79S mutation, but lacking other
known SM resistance causing mutations (n = 2), and
≧ 2 μg/ml for isolates with both the gidB mutation
and an additional known SM resistance causing mutation
(n = 4) (Table 4). The critical concentration (CC) for SM
in MGIT 960 is 1 μg/ml [47, 48]; thus, all tested isolates
with the gidB mutation were resistant to SM. However,
an MIC close or equal to the CC is likely to be missed
during routine susceptibility testing due to inter-
experiment variability. Therefore, for the purpose of
this work, we regard an MIC of 1 μg/ml as “low-level”
resistance, compared to “high-level” resistance of at
least double the CC.
The critical concentration of BDQ in MGIT was taken
to be 1 μg/ml [48]. One isolate, with a G121R mutation,
was shown to be resistant at 4 μg/ml. This mutation, as
well as S52F, was predicted to be deleterious by PRO-
VEAN analysis, while G65A was predicted to be neutral.
Fig. 2 Schematic representation of variants defining the AA1SA subclades A–C, not drawn to scale. Variants indicated in boldface are associated with drug
resistance. Variants labelled with an asterisk (*) also occur outside of these branches, but not necessarily elsewhere in the phylogeny shown in Fig. 1
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Discussion
We report the development of beyond-XDR-TB via mul-
tiple evolutionary paths. These findings are supported by
our phylogenomic analysis showing that the atypical
Beijing clade named AA1SA here appears to originate
from a single AA1-clade progenitor. Furthermore, the
AA1SA strains are closely related, resembling an out-
break which has been spreading for more than a decade
and is present in at least three South African provinces
(Fig. 1). Taken together, these factors suggest that this
strain is now endemic. Wide variation in terminal
branch lengths is observed and is believed to be a reflec-
tion of the wide geographic and temporal sampling
space. Sequencing error, which would be random, did
not contribute to the variable branch lengths, given our
stringent variant quality assurance, including a hetero-
geneity cutoff of 0.8. Furthermore, no statistical evidence
could be found for read length or average coverage to
influence branch lengths.
The phylogeny further shows the AA1SA clades A
through D in agreement with genomic drug resistance
marker combinations. This congruence supports the
phylogeny, as drug resistance markers were excluded for
its inference. The phylogeny also indicates that these
drug resistance marker combinations evolved parsimoni-
ously rather than on multiple independent occasions,
thereby suggesting the scenario that is more likely form
an evolutionary perspective.
We identified variants that are specific for AA1SA
strains, including large deletions that may be useful for
the identification of AA1SA strains. Interestingly, one of
the deletions includes Rv2017, thought to encode a tran-
scriptional regulator and to be essential for in vitro
growth [43]. The finding that this gene was deleted
questions the definition of essentiality by Himar-1
transposition.
Deleterious SNPs defining of AA1SA strains include
variants in genes with roles in transport of drugs across
the membrane (Rv1877) [49], macrotetrolide resistance
(Rv2303c; based on cross-species protein similarity) [50],
pathogenesis and reactivation from latent infection (two-
component sensor kinase, mprB) [51] and the entry of
hydrophilic molecules into the bacterial cell (ompA)
[52]. Interestingly, in addition to the deleterious
mutations, a synonymous SNP in the latter gene
(CAG276CAA) also occurs in all the AA1SA strains
(Additional file 4). We propose that these gene muta-
tions may all be plausible candidates for contributing to
a phenotype that may be better adapted to gain drug
resistance mutations and survive the fitness cost thereof.
However, roles of these variants need further investiga-
tion and while we comment on deleterious mutations,
we do not understand potentially advantageous
mutations.
AA1SA strains of clades A1 and B independently
acquired drug resistance mutations beyond the defin-
ition of XDR-TB from a highly similar genomic
background, suggesting an inherent ability to overcome
associated fitness cost. This is further affirmed by the
ability to spread, as suggested by the large number of
closely related isolates in each clade. Additional variants
with currently unknown roles uniquely occur in each
clade (Fig. 2; Additional file 5) and may contribute to
the robust phenotypes which are able to accumulate
resistance and spread. Although drug resistance
Table 3 MIC of isolates with the ethA A381P mutation
Isolate MGIT result
(cc = 5 μg/ml)
In
phylogeny
inhA
promoter
TT372 5–20 μg/ml Yes WT
TT679 5–20 μg/ml Yes WT
R3239 5–20 μg/ml Yes WT
TT545 > 20 μg/ml Yes WT
TT574 > 20 μg/ml Yes WT
TT607 > 20 μg/ml Yes WT
TT606 > 20 μg/ml No WT
TT589 > 20 μg/ml Yes WT
R4863 > 20 μg/ml Yes WT
SAWC6519 > 20 μg/ml Yes -15
R11121 > 20 μg/ml Yes -15
R13931 > 20 μg/ml Yes -17
R6768 > 20 μg/ml No WT
R9402 > 20 μg/ml No WT
R10010 > 20 μg/ml No WT
H37Rv
(no mutation control)
< 5 μg/ml Yes WT
Table 4 Minimum inhibitory concentrations of streptomycin for
strains with a gidB L79S mutation
Isolate MGIT result
(cc = 1 μg/ml)
Mutations
H37RV (control) 0.5 μg/ml –
H37MA (control) ≤ 0.5 μg/ml –
R296 ≤ 0.5 μg/ml No gidB
R3239 ≤ 0.5 μg/ml No gidB
TT372 ≤ 0.5 μg/ml No gidB
TT648 ≤ 0.5 μg/ml No gidB
R9248 1.0 μg/ml gidB L79S
R18832 1.0 μg/ml gidB L79S
TT17 > 2.0 μg/ml gidB L79S + rrs514c
TT649 > 2.0 μg/ml gidB L79S + rrs514c
TT321 > 2.0 μg/ml gidB L79S + rpsL K43R
PES16 2.0 μg/ml gidB L79S + rrs1484t
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mutations were excluded from the phylogenetic analysis,
the majority of isolates still clustered into clades A1 and
B as would be expected based only on known drug re-
sistance mutations (Fig. 1), suggesting an outbreak of
drug-resistant strains. Transmission within both clusters
A1 and B appears to occur at pre-XDR level, followed by
independent acquisition of fluoroquinolone resistance,
as is evident from the variety of gyrA mutations (Fig. 1).
However, the rrs 1401 a>g mutation represents the most
common mechanism of second-line injectable resistance.
Therefore, acquisition of this mutation on multiple occa-
sions cannot be ruled out. While the drug resistance
mutations in clade A1 isolates, inhA promoter -15 c>t
and rpoB S450 L (E. coli S531 L), as well as the compen-
satory mutation rpoC V483G individually are observed
frequently across lineages [53], the corresponding muta-
tions in clade B (inhA promoter -17 g>t and rpoB
D435V [E. coli D516V]) are rare outside of this lineage.
KatG or inhA promoter mutations can occur inde-
pendently as is expected from homoplastic variants
(Fig. 1). However, all of clades A, B and C have the same
katG mutation, supporting our assessment that katG
mutations arose before inhA promoter mutations in
these clades. Although this is the most frequently ob-
served katG mutation, further support can be found in
our earlier work [4], which shows the likelihood of the
katG mutation arising before the rrs 514- and inhA pro-
moter mutations.
A gidB L79S mutation that confers SM resistance close
to the critical concentration is present in clades A, B
and C. Certain mutations in gidB have been reported to
lead to low-level SM resistance, while dramatically in-
creasing the probability of acquisition of high-level SM
resistance by the rrs 514 a>c mutation [54]. In the pres-
ence of historic treatment regimens [55], the gidB
mutation reported here may have similarly led to the ac-
quisition of additional mutations in rrs or rpsL,
conferring higher levels of SM resistance, and thereby
weakening the regimen. This may have led to step-wise
acquisition of further resistance in the absence of appro-
priate susceptibility testing and adaptation of treatment.
Within clade C, various combinations of drug resistance
mutations evolved, lending credence to the notion that
the gidB mutation may trigger resistance acquisition.
However, it appears that very little transmission of these
clade C genotypes occur, as supported by our previous
work showing low abundance of strains with these drug
resistance profiles [4]. In contrast, clades A and B were
highly successful, based on the amount of transmission
observed. inhA promoter mutations appear to contribute
to this success when comparing the relative abundance
between clades A1 with and A2 without an inhA pro-
moter mutation. However, this observation needs to be
validated by epidemiological studies.
Interestingly, inhA promoter mutations do not make a
difference in the resistance pattern of either clade A1 or
B, in the presence of both katG and ethA mutations, that
arose before the inhA promoter mutations. Given that
inhA promoter mutations rarely occur in the absence of
any other drug resistance mutation and that they appear
to be a gateway to XDR phenotypes [56], we propose
that these mutations have a compensatory role in
addition to causing drug resistance. This demands
further investigation into the role of an inhA promoter
mutation in a background of ETH- and high-level INH
resistance. Similarly, an inhA gene mutation occurs in all
clade C isolates (Fig. 2; Additional file 5). However, this
mutation appears to be neutral according to PROVEAN
analysis and has not specifically been associated with
INH resistance to our knowledge. Given the co-
occurrence of a katG mutation in the affected strains,
site-directed mutagenesis would be required to deter-
mine its role in drug resistance.
We were surprised to find that the first drug resistance
mutation acquired was ethA A381P (Fig. 1), which is as-
sociated with ETH resistance [57], a drug widely used in
second-line treatment regimens. Interestingly, a similar
observation was made in an MDR-TB outbreak originat-
ing in the Horn of Africa, where a capreomycin resist-
ance conferring tlyA mutation was found to be present
in otherwise susceptible progenitors [58]. While it is
possible that the ethA mutation simply arose by chance,
ETH was used in the past (since the 1960s) in non-
standardised therapy, including first-line therapy [59,
60], which may explain the early acquisition and there-
fore deeply rooted evolution of this resistance marker.
Thus, the fixed nature of the marker could explain ETH
resistance in recent patients who should be ETH-naïve
according to South African guidelines [61]. The presence
of the marker in all investigated strains of this genotype
indicates that the ancestral strain most likely either had
the ethA mutation on introduction to the region or ac-
quired it soon after.
Under South African guidelines at the time when sam-
ples used in this study were collected [61], if RIF
resistance was present (either through acquisition or
transmission) and identified, the patient would be
treated with an ETH-containing second-line regimen
without routine susceptibility testing that would detect
resistance by ethA mutations. Under these conditions,
ETH-resistant strains would acquire additional resist-
ance more readily due to an inadvertently compromised
drug regimen. This is supported by the comparatively
large proportion of MDR- (27%) and pre-XDR- and
XDR-TB (93%) strains of the AA1SA genotype reported
in the EC [4], which can be explained by the inability of
the standard MDR regimen at the time to control these
strains that are already resistant to at least one second-
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line drug (ETH), as well as the companion drugs pyrazi-
namide and ethambutol. Inefficient treatment in turn
leads to extended infectiousness and transmission, per-
petuating the epidemic. Therefore, the contribution of
the ethA mutation to the epidemic is likely due to sub-
optimal diagnostic and treatment algorithms rather than
a mutation-specific physiological mechanism. While site-
directed mutagenesis to prove causality remains to be
done, it was confirmed by MIC determination that all
tested isolates with the ethA mutation, and without inhA
promoter mutations, were indeed resistant to ETH, sup-
porting the association with resistance.
A recent study of beyond-XDR-TB patients, including
patients infected with AA1SA strains, noted that 63% of
beyond-XDR patients were discharged from hospital,
having no further treatment options in the pre-
bedaquiline era. Of these, 60% had an unfavourable
outcome and 21% survived for more than 12months,
suggesting prolonged exposure of contacts [24]. In June
2018, the South African Health Ministry announced
bedaquiline (BDQ) containing regimens for all RIF-
resistant TB cases. While the decision was widely
praised, in most cases, BDQ will be prescribed without
full knowledge of available effective drugs when routine
testing is done only for INH, RIF, ofloxacin (OFX) and
amikacin (AMK), placing the long-term usefulness of
the drug at risk. While we did not conduct comprehen-
sive BDQ testing, literature reports variable association
between BDQ resistance and a large variety of different
mmpR mutations, and frameshift mutations in general
appear to cause greater increases in MIC than amino
acid changes [62]. The S52F mutation observed in our
cohort was reported by Villellas et al. to be associated
with BDQ resistance [63], and our own results suggest
at least one more BDQ-resistant case. Therefore, we
advocate caution when prescribing BDQ in patients in-
fected with strains harbouring mmpR mutations. In
Table 5, we present the 2018 WHO treatment guidelines
and show for clades A1 and B the percentage of patients
that would still benefit from each medicine. The major-
ity of cases will not benefit from fluoroquinolones or
most of the group C medicines. Based on the common
mutation profile, patients infected with clade A1 strains
are likely to benefit from a regimen composed of BDQ,
linezolid, clofazimine and CYC/TZD, with the potential
addition of delamanid (DLM). However, in a few cases,
cross-resistance to BDQ and clofazimine necessitates the
addition of a carbapenem or p-aminosalicylic acid (PAS).
In contrast, less than half of the patients infected with
clade B will benefit from the same regimen, due to wide-
spread resistance to CYC/TZD. While no known genetic
resistance markers for PAS was found in the cohort, up
to 20% of XDR-TB patients in an Eastern Cape study
were phenotypically resistant to the drug [4]. These data
demonstrate that at best some beyond-XDR-TB (clade
A1 or B infected) patients can still be treated with up to
six effective anti-TB drugs, plus adjunctive agents. In
contrast, some patients may have as little as two effective
anti-TB drugs, plus adjunctive agents left for treatment,
prompting consideration for how to treat these patients.
A recently published trial questions the value of DLM in
conjunction with an optimised background regimen
[65]. Moreover, the DLM containing regimen will be fur-
ther compromised during the continuation phase when
BDQ and DLM is discontinued. A regimen containing
fewer than four effective drugs carries the risk of losing
the value of new potent drugs due to resistance acquisi-
tion, e.g. by mutations in rv0678 as recently reported
[66]. It should also be noted that the majority of isolates
in our cohort were sampled prior to the availability of
BDQ and DLM. Thus, while it is likely an accurate rep-
resentation of pre-existing resistance, the introduction of
Table 5 Recommended drug regimens and predicted
effectivity for XDR AA1SA strains
2018 WHO-recommended grouping of MDR-TB
drugs [64]
Effectivity in AA1SA
strains
WHO grouping Anti-tuberculous
drug
Clade A1 Clade B
% cases
that
would
benefit
% cases
that
would
benefit
Group A: include all
three medicines where
possible
Levofloxacin OR
moxifloxacin
27%* 22%*
Bedaquiline 98% 96%
Linezolid 100% 100%
Group B: add one or
both medicines
Clofazimine 98% 96%
Cycloserine OR
terizidone
100% 40%
Group C: add to
complete the regimen
and when medicines
from Groups A and B
cannot be used
Ethambutol 0% 0%
Delamanid 100% 100%
Pyrazinamide 0% 0%
Imipenem-cilastatin
OR meropenem, with
clavulanic acid
Unknown
Amikacin OR
streptomycin
AMK 2%;
SM 0%
AMK 5%;
SM 0%
Ethionamide OR
prothionamide
0% 0%
p-Aminosalicylic acid 80%** 80%**
An all-oral regimen should comprise all three group A agents and at least one
group B agent, such that at least four likely effective drugs are included in the
initial phase of treatment. If only one or two group A agents are used, both
group B agents should be included in the regimen. Group C agents should be
used when an effective regimen (four likely effective agents) cannot be
constituted with group A and B drugs. Further information and specifications
can be found in [64]
*An additional 5% of strains have emerging fluoroquinolone resistance, which
is not reflected by this number
**Based on phenotypic resistance observed in an overlapping cohort [4]
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these drugs in routine care may increase the risk of
emergence of resistance to BDQ and DLM.
While these data represent a convenience set, we
are confident, based on previous [4] and additional
(Heupink, manuscript in preparation) work, that this
is a representative sampling of the true population
structure of AA1SA strains. Although the study lacks
direct evidence of treatment effectivity due to the
absence of any treatment history or outcome data,
most of the frequently occurring mutations described
here have been well-described for their roles in drug
resistance.
Unfortunately, the data analysed were too limited
(genetically similar) to support the findings on a genet-
ically inferred timescale, with insufficient correlation
between genetic divergence and sampling time. Our
time tree (Additional file 7), generated using published
mutation rates [11, 67, 68], suggests that most drug re-
sistance conferring mutations in AA1SA isolates
emerged at time points very close to or even before the
particular drug’s introduction into routine care. The lat-
ter is difficult to explain given the absence of a selective
pressure. One explanation is that the mutation rate the
AA1SA clade is different to previously published muta-
tion rates [69]. However, parallels can be drawn be-
tween the sequence of early drug resistance acquisition
and introduction of the different drugs, for example re-
lating to ETH, SM and INH.
Due to the strong influence of drug resistance muta-
tions, we are unable to distinguish between program-
matic selection and actual fitness advantage potentially
conferred by these mutations regardless of treatment
pressure. However, it is clear that drug resistance muta-
tions and possibly additional mutations influence the
way the epidemic is shaped.
Conclusion
We investigated a unique clade of atypical Beijing
(AA1SA) isolates from South Africa to address two
questions: which factors allow these strains to gain re-
sistance to virtually all available drugs on multiple occa-
sions despite supposed fitness cost associated with drug
resistance, and why are some of them so successful in
terms of transmission?
In this exploratory work, we identified various gen-
omic mutations that may lie at the root of the problem
and warrant further investigation. However, it appears
that the driver of this increased resistance acquisition
and transmission may be largely programmatic, rather
than physiological. Our results suggest that a previously
undescribed low-level SM resistance causing gidB muta-
tion likely predisposed to high-level SM resistance acqui-
sition, followed by additional resistance acquisition to all
first-line drugs. Furthermore, an unexpected deeply
rooted ethA mutation would not be detected under
current South African diagnostic algorithms [70], with
the potential to compromise an ETH-containing second-
line regimen. In addition, we found that in AA1SA
strains, inhA promoter mutations do not contribute a
drug resistance phenotype, but rather appear to increase
the fitness and transmissibility, requiring further
investigation.
These results also demonstrate that known exposure
to a drug is not an adequate indicator of resistance (e.g.
ETH, in AA1SA, or even more currently relevant, BDQ)
and it emphasises the risk of amplifying resistance as a
result of treating TB without knowledge of the full re-
sistance profile.
The development and spread of beyond-XDR-TB is a
phenomenon that is likely to occur repeatedly, as we
demonstrate it already has, demanding urgent attention.
Despite the promise of new drugs such as BDQ and
DLM, these drugs must be used as part of an evidence-
based, effective regimen. It is therefore imperative that
early reflex diagnostics be rolled out to aid the design of
appropriate, tailored treatment strategies. We support
the development of WGS technologies to accomplish ac-
curate, comprehensive resistance prediction.
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